Tags

Type your tag names separated by a space and hit enter

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Diagn Microbiol Infect Dis. 2005 Jul; 52(3):173-9.DM

Abstract

The Tigecycline Evaluation and Surveillance Trial (TEST Program) determined the in vitro activity of tigecycline over a large population of organisms from geographically diverse sites. Tigecycline was compared to amikacin, ampicillin, amoxicillin/clavulanic acid, imipenem, cefepime, ceftazidime, ceftriaxone, levofloxacin, minocycline, piperacillin/tazobactam, linezolid, penicillin, and vancomycin against 3989 commonly encountered clinical Gram-negative and Gram-positive pathogens collected from sites in the United States during 2004. The tigecycline activity was equivalent to imipenem against Enterobacteriaceae. Tigecycline inhibited extended-spectrum beta-lactamase and AmpC phenotypes at MIC90 values (minimum inhibitory concentration) of < or =2 microg/mL. In vitro results for tigecycline were similar to other broad-spectrum antimicrobial agents against nonfermenters with MIC90 results of 2 microg/mL against Acinetobacter spp. and >16 microg/mL against Pseudomonas aeruginosa. Tigecycline demonstrated potent activity against Staphylococcus aureus (MIC90, 0.25 microg/mL) and enterococci (MIC90, 0.12 microg/mL) regardless of methicillin or vancomycin susceptibility. Tigecycline MIC values were unaffected by penicillin nonsusceptibility and beta-lactamase production among fastidious respiratory pathogens (Streptococcus pneumoniae [MIC90, 0.5 microg/mL] and Haemophilus influenzae [MIC90, 0.25 microg/mL]). Tigecycline offers excellent activity against most of the commonly encountered nosocomial and community-acquired bacterial pathogens.

Authors+Show Affiliations

International Health Management Associates, Inc., Schaumburg, IL 60173-3817, USA. sbouchillon@ihmainc.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16105561

Citation

Bouchillon, Samuel K., et al. "In Vitro Activity of Tigecycline Against 3989 Gram-negative and Gram-positive Clinical Isolates From the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)." Diagnostic Microbiology and Infectious Disease, vol. 52, no. 3, 2005, pp. 173-9.
Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis. 2005;52(3):173-9.
Bouchillon, S. K., Hoban, D. J., Johnson, B. M., Johnson, J. L., Hsiung, A., & Dowzicky, M. J. (2005). In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagnostic Microbiology and Infectious Disease, 52(3), 173-9.
Bouchillon SK, et al. In Vitro Activity of Tigecycline Against 3989 Gram-negative and Gram-positive Clinical Isolates From the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis. 2005;52(3):173-9. PubMed PMID: 16105561.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). AU - Bouchillon,Samuel K, AU - Hoban,Daryl J, AU - Johnson,Brian M, AU - Johnson,Jack L, AU - Hsiung,Andre, AU - Dowzicky,Michael J, AU - ,, PY - 2005/8/18/pubmed PY - 2006/1/13/medline PY - 2005/8/18/entrez SP - 173 EP - 9 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 52 IS - 3 N2 - The Tigecycline Evaluation and Surveillance Trial (TEST Program) determined the in vitro activity of tigecycline over a large population of organisms from geographically diverse sites. Tigecycline was compared to amikacin, ampicillin, amoxicillin/clavulanic acid, imipenem, cefepime, ceftazidime, ceftriaxone, levofloxacin, minocycline, piperacillin/tazobactam, linezolid, penicillin, and vancomycin against 3989 commonly encountered clinical Gram-negative and Gram-positive pathogens collected from sites in the United States during 2004. The tigecycline activity was equivalent to imipenem against Enterobacteriaceae. Tigecycline inhibited extended-spectrum beta-lactamase and AmpC phenotypes at MIC90 values (minimum inhibitory concentration) of < or =2 microg/mL. In vitro results for tigecycline were similar to other broad-spectrum antimicrobial agents against nonfermenters with MIC90 results of 2 microg/mL against Acinetobacter spp. and >16 microg/mL against Pseudomonas aeruginosa. Tigecycline demonstrated potent activity against Staphylococcus aureus (MIC90, 0.25 microg/mL) and enterococci (MIC90, 0.12 microg/mL) regardless of methicillin or vancomycin susceptibility. Tigecycline MIC values were unaffected by penicillin nonsusceptibility and beta-lactamase production among fastidious respiratory pathogens (Streptococcus pneumoniae [MIC90, 0.5 microg/mL] and Haemophilus influenzae [MIC90, 0.25 microg/mL]). Tigecycline offers excellent activity against most of the commonly encountered nosocomial and community-acquired bacterial pathogens. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/16105561/In_vitro_activity_of_tigecycline_against_3989_Gram_negative_and_Gram_positive_clinical_isolates_from_the_United_States_Tigecycline_Evaluation_and_Surveillance_Trial__TEST_Program L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(05)00136-7 DB - PRIME DP - Unbound Medicine ER -